Skip to content

BURP trial

Symptoms of inability to Belch: UES dysrelaxation and other underlying physiological mechanisms.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23976
Enrollment
10
Registered
2020-03-30
Start date
2019-08-20
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inability to belch

Interventions

High-resolution impedance manomotry monitoring before the scheduled botox treatment

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Written informed consent; - Age above 18 years; - Complains of inability to belch, for at least 3 months.

Exclusion criteria

Exclusion criteria: - Previous treatment for inability to belch - History of pharyngeal or esophagal surgery or malignancies - Use of medication affecting esophageal motility

Design outcomes

Primary

MeasureTime frame
the ability of UES relaxation in response to esophageal distention caused by ingested air as assessed with stationary high-resolution impedance manometry

Secondary

MeasureTime frame
- To evaluate the number and type of belches, their association with reported symptoms and underlying mechanism as assessed with ambulatory 24-h impedance pH-monitoring. - To identify the number of transient lower esophageal relaxations (TLESRs) - To identify secondary peristalsis in reaction to ingested air - To assess esophageal motility, UES, and LES morphology (resting pressure, relaxation pressure, presence of hiatal hernia - To evaluate quality of life and symptoms of patients before and after Botox treatment - What is the role of aerofagia in patient with inability to belch?

Contacts

Public ContactRenske Oude Nijhuis

Amsterdam UMC

r.a.oudenijhuis@amsterdamumc.nl+31205667805

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)